And here are the numbers from the drug generating 4 Billion (with a B) for UC.
"Patients treated with adalimumab achieved a significantly higher rate of clinical remission than patients receiving placebo both at Week 8 (17% vs 9%; P=.019) and at Week 52 (17% vs 9%; P=.004).
Certainly makes the B 50% CR numbers look impressive even though they are unblinded, and uncontrolled.
It is no surprise to us why we have generated significant excitement regarding Brilacidin among patients, health care professionals and potential industry partners interested in this truly novel IBD drug candidate.